These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 32027343

  • 21. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G.
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [Abstract] [Full Text] [Related]

  • 22. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C, Wiestler B, Haller B, Schmidt-Graf F, Gempt J, Bettstetter M, Rihani L, Wu W, Meyer B, Schlegel J, Liesche-Starnecker F.
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [Abstract] [Full Text] [Related]

  • 23. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
    Tabei Y, Kobayashi K, Saito K, Shimizu S, Suzuki K, Sasaki N, Shiokawa Y, Nagane M.
    Jpn J Clin Oncol; 2021 Jan 01; 51(1):45-53. PubMed ID: 32888020
    [Abstract] [Full Text] [Related]

  • 24. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
    Ohno M, Narita Y, Miyakita Y, Matsushita Y, Arita H, Yonezawa M, Yoshida A, Fukushima S, Takami H, Ichimura K, Shibui S.
    Jpn J Clin Oncol; 2016 Jan 01; 46(1):31-9. PubMed ID: 26603354
    [Abstract] [Full Text] [Related]

  • 25. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
    Seyve A, Lozano-Sanchez F, Thomas A, Mathon B, Tran S, Mokhtari K, Giry M, Marie Y, Capelle L, Peyre M, Carpentier A, Feuvret L, Sanson M, Hoang-Xuan K, Honnorat J, Delattre JY, Ducray F, Idbaih A.
    Clin Neurol Neurosurg; 2020 Sep 01; 196():106006. PubMed ID: 32554237
    [Abstract] [Full Text] [Related]

  • 26. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.
    Cancer; 2012 Sep 15; 118(18):4545-54. PubMed ID: 22359215
    [Abstract] [Full Text] [Related]

  • 27. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H, Li J, Cheng G, Zhang J, Li X.
    Clin Neurol Neurosurg; 2016 Dec 15; 151():31-36. PubMed ID: 27764705
    [Abstract] [Full Text] [Related]

  • 28. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
    Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M.
    Neuro Oncol; 2019 Jan 01; 21(1):95-105. PubMed ID: 30277538
    [Abstract] [Full Text] [Related]

  • 29. Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study.
    Draaisma K, Chatzipli A, Taphoorn M, Kerkhof M, Weyerbrock A, Sanson M, Hoeben A, Lukacova S, Lombardi G, Leenstra S, Hanse M, Fleischeuer R, Watts C, McAbee J, Angelopoulos N, Gorlia T, Golfinopoulos V, Kros JM, Verhaak RGW, Bours V, van den Bent MJ, McDermott U, Robe PA, French PJ.
    J Clin Oncol; 2020 Jan 01; 38(1):81-99. PubMed ID: 31743054
    [Abstract] [Full Text] [Related]

  • 30. Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.
    Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, Angelov L, Barnett GH, Vogelbaum M, Ahluwalia MS.
    World Neurosurg; 2018 Aug 01; 116():e147-e161. PubMed ID: 29709748
    [Abstract] [Full Text] [Related]

  • 31. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI, Abdullah KG, McCoskey M, Binder ZA, O'Rourke DM, Desai AS, Nasrallah MP, Bigdeli A, Morrissette JJD, Brem S, Bagley SJ.
    J Neurooncol; 2019 Nov 01; 145(2):321-328. PubMed ID: 31542863
    [Abstract] [Full Text] [Related]

  • 32. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance.
    Neira JA, Ung TH, Sims JS, Malone HR, Chow DS, Samanamud JL, Zanazzi GJ, Guo X, Bowden SG, Zhao B, Sheth SA, McKhann GM, Sisti MB, Canoll P, D'Amico RS, Bruce JN.
    J Neurosurg; 2017 Jul 01; 127(1):111-122. PubMed ID: 27715437
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
    Gittleman H, Cioffi G, Chunduru P, Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS.
    Neurooncol Adv; 2019 Jul 01; 1(1):vdz007. PubMed ID: 31608326
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Drexler R, Schüller U, Eckhardt A, Filipski K, Hartung TI, Harter PN, Divé I, Forster MT, Czabanka M, Jelgersma C, Onken J, Vajkoczy P, Capper D, Siewert C, Sauvigny T, Lamszus K, Westphal M, Dührsen L, Ricklefs FL.
    Neuro Oncol; 2023 Feb 14; 25(2):315-325. PubMed ID: 35868257
    [Abstract] [Full Text] [Related]

  • 38. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y, Hata N, Mizoguchi M, Hiwatashi A, Kuga D, Hatae R, Akagi Y, Amemiya T, Fujioka Y, Togao O, Suzuki SO, Yoshimoto K, Iwaki T, Iihara K.
    Clin Neurol Neurosurg; 2019 Dec 14; 187():105556. PubMed ID: 31639630
    [Abstract] [Full Text] [Related]

  • 39. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M, Drábek J, Dwight Z, Trojanec R, Koudeláková V, Vrbková J, Kalita O, Mlcochova S, Rabcanova M, Hajdúch M.
    Klin Onkol; 2017 Dec 14; 30(5):361-371. PubMed ID: 29031038
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.